Scorr-Insert
X

Find Novel Gastroenterology Drugs in Preclinical Development in UNITED STATES

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Synthetic Biotic medicines

            Therapeutic Area: Gastroenterology

            Highest Development Status: Preclinical Product Type: Undisclosed

            Partner/Sponsor/Collaborator: AbbVie Inc

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Termination May 21, 2020

            Details:

            Upon termination, Synlogic regains all rights to develop Synthetic Biotic medicines for the potential treatment of inflammatory bowel disease (IBD).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): MORF-057

            Therapeutic Area: Gastroenterology

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 14, 2020

            Details:

            Oral presentation at ECCO highlights MORF-057 as a potent, selective and orally available small molecule development candidate

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ALPN-101

            Therapeutic Area: Gastroenterology

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 24, 2020

            Details:

            The new data demonstrate the unique potency of ALPN-101 as measured by in vitro assays involving PBMC’s from patients with Crohn’s Disease or Ulcerative colitis and in vivo mouse models of colitis.